Compare KF & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KF | MXCT |
|---|---|---|
| Founded | 1984 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.3M | 160.0M |
| IPO Year | N/A | 2021 |
| Metric | KF | MXCT |
|---|---|---|
| Price | $44.51 | $1.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 18.4K | ★ 575.1K |
| Earning Date | 01-01-0001 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $34,419,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $11.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.30 | $1.14 |
| 52 Week High | $25.56 | $5.12 |
| Indicator | KF | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 79.84 | 26.45 |
| Support Level | $40.83 | $1.19 |
| Resistance Level | $41.96 | $1.28 |
| Average True Range (ATR) | 0.79 | 0.07 |
| MACD | 0.34 | -0.02 |
| Stochastic Oscillator | 90.71 | 8.79 |
Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and Others.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.